CONMED Q2 Earnings & Revenues Beat Estimates, 2025 Outlook Raised

CONMED Corporation (CNMD) exceeded Q2 2025 expectations, reporting adjusted EPS of $1.15 and revenues of $342.3 million, both surpassing consensus estimates, primarily driven by strong performance in its General Surgery segment, notably AirSeal and Buffalo Filter. Reflecting this operational strength and improved currency trends, the company raised its full-year 2025 adjusted EPS guidance to $4.40-$4.55 and revenue outlook to $1.356-$1.378 billion, signaling management's confidence in its strategic product lines despite incorporating a 9-cent tariff impact for the second half.

Analysis

CONMED Corporation reported a solid second quarter for 2025, exceeding consensus estimates with an adjusted EPS of $1.15 (+17.3% YoY) and revenues of $342.3 million (+3.1% YoY). The performance was primarily driven by the General Surgery segment, which grew 4.7% on strong, double-digit gains from its AirSeal and Buffalo Filter product lines. In contrast, the Orthopedic Surgery segment saw modest growth of 0.9%, hampered by a 0.8% sales decline in the United States, which was offset by international performance. Despite the revenue beat, the report contains points of caution: GAAP EPS declined to 69 cents from 96 cents in the prior-year period, selling and administrative expenses rose a significant 11% YoY, and cash flow from operations fell to $29.1 million from $43.3 million. Positively, the company demonstrated operational leverage with adjusted gross and operating margins expanding by 120 and 110 basis points, respectively. Management signaled confidence by raising its full-year 2025 guidance, now projecting adjusted EPS of $4.40-$4.55, which notably absorbs an anticipated 9-cent negative impact from tariffs, suggesting strong underlying operational momentum.

Key Decisions for Investors

• Investors should view the raised full-year guidance as a key positive, as it indicates management's confidence in offsetting tariff headwinds and supply constraints with operational strength in its core growth platforms like AirSeal.
• It is critical to scrutinize the 11% increase in selling and administrative expenses and the significant year-over-year decline in operating cash flow, which could signal pressure on future profitability if not addressed.
• Monitor the performance of the U.S. Orthopedic Surgery segment, as its 0.8% sales decline presents a notable weakness that contrasts with the strength in General Surgery and international markets.
• Consider the Q3 guidance of $330-$337 million in revenue and $1.03-$1.08 in adjusted EPS as a near-term benchmark to validate that the company's positive momentum is sustainable.